| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Sheng,Bao-Xi | Chairman | 4.88% | |
| TA YA VENTURE CAPITAL CO., LTD. | Director | 3.90% | |
| Chen,Shi-Min | Director | 1.05% | |
| Chen,Guan-Bai | Director | 18.03% | Baolei Co. Ltd. |
| Lai,Ming-Rong | Independent Director | 0.00% | |
| Li,Yi-Qin | Independent Director | 0.00% | |
| Lin,Rui-Yi | Independent Director | 0.00% | |
| Lin,Xin-Yi | Independent Director | 0.00% |
Change Company Name to BORA PHARMACEUTICALS CO., LTD.
2024/07/01
Change Capital to 2,000,000,000
2023/06/14
Change Company Name to BAORUI PHARMACEUTICAL CO., LTD. (FORMER NAME: BAORUI INTERNATIONAL CO., LTD.)
2022/09/16
Change Capital to 1,200,000,000
2021/07/30
Change Capital to 600,000,000
2019/06/19
Change Capital to 350,000,000
2017/05/05
Change Company Name to BORA PHARMACEUTICALS CO., LTD.
2013/06/03
Change Capital to 250,000,000
2013/03/04
Change Capital to 124,000,000
2013/02/01
Change Capital to 40,000,000
2012/12/25
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 4,479,585 | 19,245,907 | 14,200,068 |
| Operating cost | 2,590,088 | 11,535,632 | 7,208,830 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 1,889,497 | 7,710,275 | 6,991,238 |
| Unrealized profit (loss) on sales of goods | 51 | - | - |
| Realized profit (loss) on sales of goods | 40 | - | - |
| Operating gross profit (loss), net | 1,889,486 | 7,710,275 | 6,991,238 |
| Operating expenses | 1,208,114 | 4,327,654 | 1,742,099 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 681,372 | 3,382,621 | 5,249,139 |
| Non-operating income and expenses | 2,336,028 | 1,572,360 | -1,184,993 |
| Net profit (loss) before tax | 3,017,400 | 4,954,981 | 4,064,146 |
| Income tax expense (benefits) | 266,692 | 914,578 | 992,225 |
| Net profit (loss) of ongoing business for the current period | 2,750,708 | 4,040,403 | 3,071,921 |
| Profit (loss) of closed units | -1,341,923 | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 1,408,785 | 4,040,403 | 3,071,921 |
| Other comprehensive profit (loss), net | 201,846 | 291,096 | 34,279 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 1,610,631 | 4,331,499 | 3,106,200 |
| Net profit (loss) attributable to owners of parent company | 1,399,273 | 3,939,009 | 3,030,142 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | 9,512 | 101,394 | 41,779 |
| Comprehensive profit (loss) attributable to owners of parent company | 1,601,060 | 4,227,510 | 3,064,856 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 9,571 | 103,989 | 41,344 |
| Basic earnings per share (yuan) | 13 | 38 | 30 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 1,344,957 | 980,808 | 4,613,657 |
| Net cash inflows (outflows) from investing activities | -1,296,737 | -10,680,386 | -2,457,585 |
| Net cash inflow (outflow) from financing activities | -867,773 | 12,070,618 | -2,440,223 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 115,991 | 404,863 | 56,126 |
| Increase (decrease) in cash and cash equivalents in the current period | -703,562 | 2,775,903 | -228,025 |
| Beginning balance of cash and cash equivalents | 5,829,197 | 3,053,294 | 3,281,319 |
| Ending balance of cash and cash equivalents | 5,125,635 | 5,829,197 | 3,053,294 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 21,934,452 | 23,565,691 | 10,603,028 |
| Non-current asset | 24,824,201 | 22,033,243 | 14,448,977 |
| Total asset | 46,758,653 | 45,598,934 | 25,052,005 |
| Current liability | 15,441,986 | 13,808,597 | 8,229,061 |
| Non-current liability | 16,161,649 | 16,778,772 | 5,057,133 |
| Total liability | 31,603,635 | 30,587,369 | 13,286,194 |
| share capital | 1,037,174 | 1,033,119 | 1,014,981 |
| Equity - secruity token | - | - | - |
| capital reserve | 4,570,291 | 4,408,236 | 3,318,350 |
| retained earning | 6,971,904 | 7,106,920 | 4,728,617 |
| Other equity | 562,353 | 362,308 | 73,807 |
| Treasury stock | -42,651 | -43,181 | -50,968 |
| Total equity attributable to owners of parent company | 13,099,071 | 12,867,402 | 9,084,787 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 2,055,947 | 2,144,163 | 2,681,024 |
| Total Equity | 15,155,018 | 15,011,565 | 11,765,811 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 260,196 | 226,715 | 85,320 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 241,000 | 244,000 | 288,000 |
| Net asset value per share | 126 | 124 | 89 |
Others
2014
Confirmation of the existence of employment relationship, etc
2014
Infringement of patent rights related to property rights disputes, etc.
2018, 2019
Return deposit
2015
Exercise rights
2015, 2017
Petition for trial
2016, 2017
Return security deposit
2018, 2019
Delivery of court audio CDs
2023
Request for damage compensation
2017
Infringement damage compensation
2015, 2016, 2017
Motion of objection for provisional attachment
2015
